The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I clinical trial testing the safety of IL-21-expanded, off-the-shelf, natural killer cells for relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome.
 
Sumithira Vasu
Research Funding - The Ohio State University Wexner Medical Center (Inst)
 
Nidhi Sharma
No Relationships to Disclose
 
Lynn Odonnell
No Relationships to Disclose
 
Kevin Bosse
No Relationships to Disclose
 
Dean Anthony Lee
Leadership - Cyto-Sen Therapeutics
Stock and Other Ownership Interests - Caribou Biosciences; Courier Therapeutics; Cyto-Sen Therapeutics
Honoraria - Miltenyi Biotec
Consulting or Advisory Role - Caribou Biosciences; Courier Therapeutics; Cyto-Sen Therapeutics; Intellia Therapeutics; Merck Sharp & Dohme
Patents, Royalties, Other Intellectual Property - US 60/925,830, PCT/US2008/061342 US 62/404,520 US 62/623,682 US 18/20,187
Travel, Accommodations, Expenses - Cyto-Sen Therapeutics; Merck Sharp & Dohme; Shire